Hill July 9, 2023
The Food and Drug Administration (FDA) on Thursday gave full approval to Leqembi, the first drug that can change the course of Alzheimer’s disease. The move gives patients a glimmer of hope, and patient advocates and some doctors say it’s the beginning of a new era of Alzheimer’s treatment.
But there are lingering questions about the drug’s safety, cost, effectiveness and accessibility.
Here are five things to know:
Leqembi is meant only for people in the very early stages of Alzheimer’s disease
Alzheimer’s disease affects more than 6 million Americans. Scientists have been searching for an effective treatment for decades and still don’t know what causes the disease, which is ultimately 100 percent fatal.
Leqembi, developed by Eisai...
Today's Sponsors
Today's Sponsor